Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Other Non-Current Liabilities for 9 years, with the latest figure at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 392.91% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.3 million (up 392.91% YoY), and the FY2025 full-year result was $18.5 million, up 916.02% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $25.3 million, up from $18.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $25.3 million in Q1 2026, with the low at $260000.0 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $5.4 million across 5 years, with a median of $1.9 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 77.21% — and 2025, when it jumped 916.02%.
• Kiniksa Pharmaceuticals International's Other Non-Current Liabilities stood at $1.8 million in 2022, then gained by 1.03% to $1.9 million in 2023, then retreated by 1.88% to $1.8 million in 2024, then jumped by 916.02% to $18.5 million in 2025, then jumped by 36.68% to $25.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $25.3 million (Q1 2026), $18.5 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.